4 major cardiology trends you need to know from TCT 2022

Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive.

The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations.

Medtronic, Abbott, Edwards and Boston Scientific represent a few of the companies revealing new data for their cardiovascular offerings. ReCor Medical, Abiomed and more got involved, too.

Plenty of the study outcomes represented positive steps forward, while other companies hit speed bumps in their efforts. Here are some of the biggest takeaways from the conference:

1. Renal denervation innovations plug along

Medtronic (NYSE:MDT) announced study data that demonstrates significant blood pressure reduction with the Symplicity renal denervation system.

The RDN minimally invasive procedure delivers radiofrequency energy to specific nerves near the …

Read more
  • 0

Medtronic presents positive data on TAVR, TMVR devices

Medtronic Evolut TAVR. [Image from Medtronic]Medtronic (NYSE:MDT) announced data from multiple trials supporting its transcatheter heart valve replacement devices.

Data were presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston. Results covered the company’s self-expanding transcatheter aortic valve replacement (TAVR) devices and its transapical transcatheter mitral valve replacement (TMVR) system.

Medtronic kicked off TCT by announcing the full U.S. launch of its next-generation Evolut FX TAVR system.

Examining HALT in Medtronic CoreValve and Evolut program

The Pathological Study of Hypo-Attenuated Leaflet Thickening (HALT) represents part of the CoreValve and Evolut program. It compares microCT and histology findings of valve leaflet thickening. Medtronic said in a news release that the trial is the first to compare such things. It may provide clinical insights into the long-term durability of transcatheter aorti…

Read more
  • 0

CardioMech performs first in-person procedure with transcatheter mitral valve repair tech

CardioMech yesterday confirmed the completion of the first procedure with its transcatheter mitral valve repair (TMVR) technology.

The patient, diagnosed with severe symptomatic degenerative mitral regurgitation (DMR) was evaluated by Sanger Heart & Vascular Institute’s multidisciplinary heart team and offered a choice between open-heart surgery (the standard of care) or the new, investigational CardioMech MVRS, according to a report from Atrium Health.

Minneapolis-based CardioMech’s transcatheter transseptal chordal mitral valve repair technology is currently enrolling in an FDA investigational device exemption (IDE)-approved early feasibility study and is not yet commercially available in the U.S. or anywhere else around the globe.

The procedure was conducted in early September 2021, marking the first time the CardioMech MVRS technology had been used in a human

“For over a decade, we’ve been a leader and innovator in transcathete…

Read more
  • 0

Abbott’s MitraClip receives boost as CMS expands coverage for TMVR

The MitraClip TMVR device [Image courtesy of Abbott]Abbott (NYSE:ABT) announced today that CMS revised its coverage for TMVR, opening up new possibilities for its MitraClip device.

The CMS National Coverage Determination (NCD) expands coverage for transcatheter mitral valve repair (TMVR) to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure.

According to an Abbott news release, the CMS decision significantly increases the number of people eligible for insurance coverage for mitral valve repair with MitraClip. Abbott said the revision is critically important to secondary MR patients as most impacted by MR are older, while several would be required to pay out of pocket for the procedure, creating a barrier of access.

“Secondary mitral regurgitation generally impacts older individuals suffering from heart failure who rely on Medicare for their healthcare coverage,” Abbott structural heart business…

Read more
  • 0